

Aaron M Allen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6877470/publications.pdf>

Version: 2024-02-01

31
papers

1,207
citations

758635

12
h-index

476904

29
g-index

33
all docs

33
docs citations

33
times ranked

1435
citing authors

#	ARTICLE	IF	CITATIONS
1	Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 640-645.	0.4	345
2	BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1128-1137.	0.5	160
3	Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extracranial Irradiation for Extensive-Disease Small Cell Lung Cancer (ED SCLC): NRG Oncology RTOG 0937. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1561-1570.	0.5	131
4	The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. <i>Lancet, The</i> , 2022, 399, 1886-1901.	6.3	89
5	Assessment of response of brain metastases to radiotherapy by PET imaging of apoptosis with 18F-ML-10. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1400-1408.	3.3	65
6	Influence of Radiotherapy Technique and Dose on Patterns of Failure for Mesothelioma Patients After Extrapleural Pneumonectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1366-1374.	0.4	56
7	Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma. <i>Radiation Oncology</i> , 2017, 12, 163.	1.2	55
8	Restricted Field IMRT Dramatically Enhances IMRT Planning for Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1587-1592.	0.4	49
9	Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi). <i>Lung Cancer</i> , 2018, 124, 117-124.	0.9	46
10	Pneumonectomy after chemoradiation. <i>Cancer</i> , 2008, 112, 1106-1113.	2.0	41
11	Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer. <i>Oncolimmunology</i> , 2021, 10, 1959979.	2.1	23
12	CPAP (Continuous Positive Airway Pressure) is an effective and stable solution for heart sparing radiotherapy of left sided breast cancer. <i>Radiation Oncology</i> , 2020, 15, 59.	1.2	13
13	The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. <i>Oncology</i> , 2021, 99, 555-561.	0.9	13
14	Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy. <i>Journal of Clinical Neuroscience</i> , 2016, 26, 46-49.	0.8	12
15	Stereotactic body radiotherapy for central lung tumors, yes we can!. <i>Radiation Oncology</i> , 2018, 13, 77.	1.2	12
16	Retropharyngeal Nodes in Hypopharynx Cancer on Positron Emission Tomography. <i>Journal of Clinical Oncology</i> , 2007, 25, 599-601.	0.8	11
17	Evaluation of the dose calculation accuracy in intensity-modulated radiation therapy for mesothelioma, focusing on low doses to the contralateral lung. <i>Journal of Applied Clinical Medical Physics</i> , 2009, 10, 34-42.	0.8	11
18	Can Hyperpolarized Helium MRI add to radiation planning and follow-up in lung cancer?. <i>Journal of Applied Clinical Medical Physics</i> , 2011, 12, 169-183.	0.8	10

#	ARTICLE	IF	CITATIONS
19	Endobronchial brachytherapy provides excellent long-term control of recurrent granulation tissue after tracheal stenosis. <i>Brachytherapy</i> , 2012, 11, 322-326.	0.2	10
20	Efficacy and Safety of <i>ALK</i> Tyrosine Kinase Inhibitors in Elderly Patients with Advanced <i>ALK</i>-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort. <i>Oncology Research and Treatment</i> , 2019, 42, 275-282.	0.8	10
21	Endobronchial brachytherapyâ€™A novel approach for the management of airway amyloidosis. <i>Brachytherapy</i> , 2018, 17, 966-972.	0.2	9
22	BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors. <i>Frontiers in Oncology</i> , 2021, 11, 603223.	1.3	9
23	High-Dose Radiotherapy as Neoadjuvant Treatment in Non-Small-Cell Lung Cancer. <i>Oncology</i> , 2018, 95, 13-19.	0.9	7
24	Intensityâ€™modulated radiotherapy is a safe and effective treatment for localized malignant pleural mesothelioma. <i>Thoracic Cancer</i> , 2018, 9, 1470-1475.	0.8	7
25	Can Ipilimumab restore immune response in advanced NSCLC after progression on antiâ€™PD â€ / PDâ€™L1 agents?. <i>Thoracic Cancer</i> , 2020, 11, 2331-2334.	0.8	5
26	Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced nonâ€™smallâ€™cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, e125-e131.	0.7	3
27	Lung Cancer in Israel. <i>Journal of Thoracic Oncology</i> , 2020, 15, 493-498.	0.5	2
28	Stereotactic body radiation therapy (SBRT) for the treatment of primary lung cancer in recipients of lung transplant. <i>Radiology and Oncology</i> , 2020, 54, 227-232.	0.6	2
29	Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity. <i>Journal of Cardiothoracic Surgery</i> , 2019, 14, 7.	0.4	1
30	The impact of PET-CT on staging, management, and prognostication of small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6611-6611.	0.8	0
31	Rare targetable drivers (RTD) in NSCLC: PD-L1 expression, tumor mutation burden (TMB), microsatellite instability (MSI) and outcomes with immune check-point inhibitors (ICPi).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9076-9076.	0.8	0